Understanding the GLP-1 consumer The GLP-1 era has given rise to multiple distinct consumer types, each with shared, yet nuanced, nutritional needs: Consumers currently using GLP-1 therapies face unique challenges, including appetite suppression that can make meeting nutritional requirements difficult, potential gastrointestinal side effects and concerns about maintaining muscle mass during weight loss
Truveta is trusted by leading public health, life science, healthcare, and academic organizations to accelerate discovery and adoption of new therapies, improve clinical trials, and enhance patient care
Doses exceeding 2,000 mg per day are generally considered high and are more likely to cause gastrointestinal side effects
(Study: Akkermansia muciniphila and metabolic health during a dietary intervention Gut , BMJ) GLP-1 Medications vs Microbiome Regulation They are not substitutes
muciniphila abundance in these patients ( Akkermansia population and weight reduction, increased insulin production, and reduced hepatic and muscle fat in mice supplemented with inulin ( The accumulation of visceral fat that occurs in obesity is a risk factor for the development of T2D as its lipolytic activity and greater recruitment of macrophages with a pro-inflammatory phenotype favor insulin resistance ( A